Home > News > Clinical trials put dendrimers on course for treating HIV
September 24th, 2003
Clinical trials put dendrimers on course for treating HIV
They might be nano’s artificial molecule, but dendrimers are taking real steps toward fighting HIV and sexually transmitted diseases in women. Starpharma Pooled Development Ltd. of Melbourne, Australia, gained approval in July from the U.S. Food and Drug Administration to start human trials of VivaGel, a dendrimer-based topical gel designed to prevent or reduce disease transmission during sexual intercourse. It’s the first dendrimer – and defined nanostructure – cleared for clinical testing, according to John Raff, Starpharma’s chief executive.
'Electronic skin' could improve early breast cancer detection October 29th, 2014
Tiny carbon nanotube pores make big impact October 29th, 2014
Molecular beacons shine light on how cells 'crawl' October 27th, 2014
New nanodevice to improve cancer treatment monitoring October 27th, 2014